HOW HAVE BIOSIMILARS PERFORMED IN IBD?

Papamichael et al. AP&T 2015
Clinical Response 33% -100% (most > 60%) and Remission 38% -100% (most > 65%):remember no IBD head-head BSM vs Reference
Clinical Experience with CT-P13 in IBD: Updated Systematic Review
• 13 studies in Korea, Hungary, Czech, Norway, Netherlands, Italy involving at least 500 IBD patients who were switched from IFX to CT-P13 • Treatment persistency ranged 57%-88% at end of follow-up • Adverse events in the range of expected • Infusion reactions up to 6.6%
• ATI in the range of expected -"…worsening in disease specific composite measure or consensus between investigator and patient leading to major change in therapy"
• Non-inferiority, margin of 15% 
NOR-SWITCH (Jørgensen, et al. abstract LB15) Presented at UEGW (Vienna) 2016
• Phase IV multi-indication prospective non-medical switch study in Norway by Norwegian govt. -52w randomized, double blind non inferiority study
• RESULTS:
-Primary outcome: disease worsening at 12 months -Anti-drug antibodies:
• Remicade 7.1%
• CT-P13 7.9% …..We probably shouldn't take this approach to biosimilars…...
